Galmed COO reports initial share and RSU holdings

Galmed Pharmaceuticals Chief Operating Officer Nehemya Guy filed an initial ownership report showing his equity stake in the company.

Rhea-AI Filing Summary

Galmed Pharmaceuticals Chief Operating Officer Nehemya Guy filed an initial ownership report showing his equity stake in the company. He directly owns 22,116 Ordinary Shares, along with stock options and multiple restricted share unit (RSU) awards.

He holds three option grants to purchase Ordinary Shares, each covering 222 underlying shares at an exercise price of $68.40, with expiration dates in 2028, 2029, and 2030. In addition, he holds RSU awards covering 2,083, 23,333 and 25,000 shares that vest between 2026 and 2028, subject to his continued service.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Nehemya Guy

Role Chief Operating Officer

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Restricted Share Units	--	--	--
holding	Restricted Share Units	--	--	--
holding	Restricted Share Units	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 666 contracts (Direct); Ordinary Shares — 22,116 shares (Direct); Restricted Share Units — 50,416 shares (Direct)

Footnotes (3)

1. F1. These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.
2. F2. These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.
3. F3. These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Galmed Pharmaceuticals (GLMD) COO Nehemya Guy report owning in this Form 3?

He reports direct ownership of 22,116 Ordinary Shares plus options and RSUs. The filing lists three option grants over 222 underlying shares each at $68.40, and several restricted share unit awards that together represent additional future share-based compensation.

What stock options for Galmed Pharmaceuticals (GLMD) does COO Nehemya Guy hold?

He holds three option grants to purchase Ordinary Shares at $68.40 per share. Each grant is tied to 222 underlying shares, with expiration dates in 2028, 2029 and 2030, reflecting long-dated incentives aligned with Galmed’s longer-term performance.

How many restricted share units does GLMD COO Nehemya Guy have and when do they vest?

He holds RSU awards over 2,083, 23,333 and 25,000 shares. Footnotes state these units vest in tranches between August 2026 and August 2028, with vesting conditioned on his continued service at Galmed Pharmaceuticals.

Is this Galmed Pharmaceuticals (GLMD) filing a new insider trade or an initial ownership report?

This is an initial Form 3 ownership report, not a buy or sell trade. The transactions are coded as holdings, with no shares reported as purchased or sold, and all transaction directions marked as unknown in the summary data.

Does Galmed Pharmaceuticals’ COO hold his GLMD equity directly or through entities?

All reported holdings are listed as directly owned. The filing shows ownership type and codes as direct for the Ordinary Shares, options and restricted share units, with no indication of indirect ownership through trusts or other entities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 07:45 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Nehemya Guy

(Last) (First) (Middle)

C/O MEITAR LAW OFFICES

16 ABBA HILLEL SILVER RD.

(Street)

RAMAT GAN 5250608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Galmed Pharmaceuticals Ltd. [ GLMD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	22,116	D
Restricted Share Units	2,083(1)	D
Restricted Share Units	23,333(2)	D
Restricted Share Units	25,000(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares	11/10/2020	11/10/2030	Ordinary Shares	222	$68.4	D
Options to Purchase Ordinary Shares	12/17/2019	12/17/2029	Ordinary Shares	222	$68.4	D
Options to Purchase Ordinary Shares	07/10/2018	07/10/2028	Ordinary Shares	222	$68.4	D

Explanation of Responses:

1. These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.

2. These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.

3. These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

	/s/ Guy Nehemya	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)